As Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash

Compass Pathways delays key Phase 3 psilocybin trial readouts, triggering a 30% workforce reduction amid efforts to conserve cash and refocus.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *